Prothelia Is Developing Recombinant Human Laminin 111Rhlam 111For Treatment Of Congenital Muscular Dystrophy Type 1A This Form Of Muscular Dystrophy Is Also Referred To As Mdc1Amerosin Deficiency Or Lama2 Deficiency
No conferences found for this company.
| Company Name | Prothelia Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
Enter your address and we will specify the offer for your area.